Amedisys Inc (AMED) 51.80 $AMED Shares of AMED Up 43.1%

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 2:08 PM

Amedisys Inc (AMED) 51.80 $AMED

Shares of AMED Up 43.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 03, 12:51PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 4 months, Amedisys has returned 43.12% as of today's recent price of $52.36.
AMED: 51.80 (-1.00)

Amedisys to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 3:00PM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading healthcare at home companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York, NY on Wednesday, June 8, 2016.
AMED: 51.80 (-1.00)

Uptrend Call Working As Amedisys Stock Rises 39.9% (AMED)
Comtex SmarTrend(R) - Fri May 27, 12:30AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 39.94% as of today's recent price of $51.19.
AMED: 51.80 (-1.00)

Amedisys Has Returned 37.8% Since SmarTrend Recommendation (AMED)
Comtex SmarTrend(R) - Thu May 19, 12:56PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 37.75% as of today's recent price of $50.39.
AMED: 51.80 (-1.00)

Amedisys Up 40.8% Since SmarTrend Uptrend Call (AMED)
Comtex SmarTrend(R) - Thu May 12, 12:26AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 40.76% as of today's recent price of $51.49.
AMED: 51.80 (-1.00)

Amedisys to Present at the Bank of America Merrill Lynch Health Care Conference
GlobeNewswire - Fri May 06, 9:00AM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading healthcare at home companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the 2016 Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016.
AMED: 51.80 (-1.00)

Amedisys (AMED) Lags Q1 Earnings, Revenues Top the Mark
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:56AM CDT
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 33 cents per share in the first quarter of 2016.
BSX: 23.02 (-0.30), AFAM: 42.11 (-0.81), AMED: 51.80 (-1.00), HLS: 40.54 (-1.02)

Amedisys Reports First Quarter Financial Results
GlobeNewswire - Tue May 03, 4:31PM CDT
Amedisys, Inc. (NASDAQ:AMED), a leading home health and hospice company, today reported its financial results for the three-month period ended March 31, 2016.
AMED: 51.80 (-1.00)

Chemed (CHE) Q1 Earnings Miss the Mark, Revenues in Line
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:53AM CDT
Chemed Corp. (CHE) reported first-quarter 2016 adjusted earnings per share (EPS) of $1.53.
CHE: 132.09 (-1.78), AFAM: 42.11 (-0.81), AMED: 51.80 (-1.00), HLS: 40.54 (-1.02)

Amedisys Shares Up 42.1% Since SmarTrend's Buy Recommendation (AMED)
Comtex SmarTrend(R) - Wed Apr 27, 12:19AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 2 months, Amedisys has returned 42.13% as of today's recent price of $51.99.
AMED: 51.80 (-1.00)

Amedisys Announces First Quarter Earnings Release and Conference Call Date
GlobeNewswire - Tue Apr 26, 3:03PM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading home health and hospice care companies, announced today that it will report results for the first quarter ended March 31, 2016 after the market closes on May 3, 2016. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2016.
AMED: 51.80 (-1.00)

Amedisys Welcomes Three New Members To Its Board Of Directors
GlobeNewswire - Tue Apr 26, 8:00AM CDT
Amedisys Inc. (NASDAQ:AMED), a leading home health, hospice and personal care company, today announced the addition of three new members to its Board of Directors.
KND: 11.52 (-0.61), SYBT: 27.70 (-0.29), AMED: 51.80 (-1.00)

Quest Diagnostics (DGX) Q1 Earnings in Line, Volume Up
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:23AM CDT
Quest Diagnostics' (DGX) first-quarter 2016 adjusted earnings per share (EPS) of $1.12 came in line with the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), AFAM: 42.11 (-0.81), DGX: 77.45 (-1.30), AMED: 51.80 (-1.00)

AmSurg Poised on Strategic Buyouts, Rising Costs a Concern
Zacks Equity Research - Zacks Investment Research - Wed Apr 20, 4:46PM CDT
On Apr 18, 2016, we issued an updated research report on Nashville, TN-based AmSurg Corp. (AMSG).
AMSG: 80.11 (-0.89), BSX: 23.02 (-0.30), AFAM: 42.11 (-0.81), AMED: 51.80 (-1.00)

Moving Average Crossover Alert: Amedisys (AMED)
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 9:11AM CDT
Amedisys Inc. (AMED) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
AMED: 51.80 (-1.00)

Amedisys Shares Up 29.0% Since SmarTrend's Buy Recommendation (AMED)
Comtex SmarTrend(R) - Tue Apr 12, 1:43PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 2 months, Amedisys has returned 28.95% as of today's recent price of $47.17.
AMED: 51.80 (-1.00)

Amedisys Poised on Balanced Growth, Strategic Buyouts
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 1:35PM CDT
On Apr 11, 2016, we issued an updated research report on Amedisys Inc. (AMED).
AFAM: 42.11 (-0.81), CSII: 18.36 (+0.41), RMD: 59.80 (-0.70), AMED: 51.80 (-1.00)

DaVita to Acquire Mountain View, Expand Footprint in Colorado
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 1:35PM CDT
DaVita HealthCare Partners Inc. (DVA) intends to acquire Mountain View Medical Group to enhance its kidney care services and extend footprint in Colorado Springs.
ABUS: 3.60 (-0.33), AFAM: 42.11 (-0.81), DVA: 76.08 (-1.13), AMED: 51.80 (-1.00)

Falling Earnings Estimates Signal Weakness Ahead for RadNet (RDNT)
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 7:51AM CDT
RadNet has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
RDNT: 5.29 (-0.14), AMED: 51.80 (-1.00)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CassTime's AI Solution Eases Global Parts Market Strains

Driving Innovation in the Auto Aftermarket When car parts become a global jigsaw puzzle, you need more than wrenches to solve it. Enter CassTime with its AI-driven 'T+D Solution'—a tangible answer to the woes of data matching and repair capability bottlenecks plaguing the automotive aftermarket worldwide. Taming the Global Parts Beast Pull back the curtain on AAPEX 2026...

Cultural Bridges and Mazu's Spirit: Gen Z's Role

Youthful Energy Revives Ancient Traditions Over in Putian, China, you'd have seen a curious sight in late October—hundreds of young folks from over 20 corners of the globe gathering not for a concert or some influencer meet-up, but to dive into Mazu's legacy. This ain't your typical cultural event. More than 200 Gen Z representatives came together, bridging their...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

7th World Media Summit Spotlights Media's Future in Beijing

The Changing Landscape of Global Media An event of this magnitude doesn't just pop up every day like a stock ticker on Wall Street. This year's 7th World Media Summit in Beijing is where nearly 500 bigwigs from all corners of the media landscape are converging. It's not about trading stocks or hitting quarterly numbers—it's about shaping how stories get told in an era...

JOYEE N01 Kicks Off Global Launch with African Orders

A New Chapter for JOYEE N01 There's a moment in every company's life when it either steps boldly into the future or stumbles back into obscurity. For FAW Bestune, October 28, 2026, was one of those defining moments. On this day, they launched global mass production of the JOYEE N01 in Yancheng, China. And boy, did they pull out all the stops—you don't see this kind of...

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

ecozy's Brezzano Switch: Brewing Simplicity at Home

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

2027 Toy of the Year Finalists Energize Play Market

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

FuelCell Faces Class Action Crunch as Deadline Looms

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...